Literature DB >> 22419176

The evolution of personalized cancer genetic counseling in the era of personalized medicine.

Hetal S Vig, Catharine Wang.   

Abstract

Practice changes in cancer genetic counseling have occurred to meet the demand for cancer genetic services. As cancer genetics continues to impact not only prevention strategies but also treatment decisions, current cancer genetic counseling models will need to be tailored to accommodate emerging clinical indications. These clinical indications include: surgical prophylactic bilateral mastectomy candidates, PARP-inhibitor candidates, patients with abnormal tumor screening results for Lynch syndrome, and post-test counseling patients (after genetic testing is ordered by another healthcare provider). A more personalized, multidisciplinary approach to selecting the best framework, for a given clinical indication, may become increasingly necessary in this era of personalized medicine.

Entities:  

Mesh：

Year:  2012        PMID： 22419176      PMCID： PMC3905734          DOI： 10.1007/s10689-012-9524-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN： 1389-9600            Impact factor:   2.375


  51 in total

1.  Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.

Authors:  Edibaldo Silva; Henry Lynch
Journal:  Breast J       Date:  2006 May-Jun       Impact factor: 2.431

Review 2.  Decision aids for people facing health treatment or screening decisions.

Authors:  A M O'Connor; D Stacey; D Rovner; M Holmes-Rovner; J Tetroe; H Llewellyn-Thomas; V Entwistle; A Rostom; V Fiset; M Barry; J Jones
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  A comparison of patient satisfaction with telehealth and on-site consultations: a pilot study for prenatal genetic counseling.

Authors:  Debra J Abrams; Mark R Geier
Journal:  J Genet Couns       Date:  2006-06       Impact factor: 2.537

4.  An assessment of the efficacy of cancer genetic counselling using real-time videoconferencing technology (telemedicine) compared to face-to-face consultations.

Authors:  Jordanna Joaquina Coelho; Angela Arnold; Jeremy Nayler; Marc Tischkowitz; James MacKay
Journal:  Eur J Cancer       Date:  2005-10       Impact factor: 9.162

5.  Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.

Authors:  Alan J Stolier; George M Fuhrman; Lynnette Mauterer; John S Bolton; Duane W Superneau
Journal:  Breast J       Date:  2004 Nov-Dec       Impact factor: 2.431

6.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  Regaining the initiative. Forging a new model of the patient-physician relationship.

Authors:  J Balint; W Shelton
Journal:  JAMA       Date:  1996-03-20       Impact factor: 56.272

8.  Clinical genetics issues encountered by family physicians.

Authors:  Louise S Acheson; Kurt C Stange; Stephen Zyzanski
Journal:  Genet Med       Date:  2005-09       Impact factor: 8.822

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.

Authors:  Marc D Schwartz; Caryn Lerman; Barbara Brogan; Beth N Peshkin; Chanita Hughes Halbert; Tiffani DeMarco; William Lawrence; David Main; Clinton Finch; Colette Magnant; Marie Pennanen; Theodore Tsangaris; Shawna Willey; Claudine Isaacs
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 50.717
View more
  9 in total

1.  Risk for Patient Harm in Canadian Genetic Counseling Practice: It's Time to Consider Regulation.

Authors:  Andrea L Shugar; Nada Quercia; Christopher Trevors; Marina M Rabideau; Sohnee Ahmed
Journal:  J Genet Couns       Date:  2016-06-07       Impact factor: 2.537

Review 2.  100 years Lynch syndrome: what have we learned about psychosocial issues?

Authors:  Eveline M A Bleiker; Mary Jane Esplen; Bettina Meiser; Helle Vendel Petersen; Andrea Farkas Patenaude
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 3.  MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.

Authors:  Sofia Mason; Kerrie McDonald
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

4.  Analysis of Advantages, Limitations, and Barriers of Genetic Counseling Service Delivery Models.

Authors:  Stephanie A Cohen; Rachelle C Huziak; Shanna Gustafson; Robin E Grubs
Journal:  J Genet Couns       Date:  2016-01-14       Impact factor: 2.537

5.  Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.

Authors:  Sonya Reid; Sydney Cadiz; Tuya Pal
Journal:  Curr Breast Cancer Rep       Date:  2020-05-19

6.  Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling.

Authors:  Morgan Butrick; Scott Kelly; Beth N Peshkin; George Luta; Rachel Nusbaum; Gillian W Hooker; Kristi Graves; Lisa Feeley; Claudine Isaacs; Heiddis B Valdimarsdottir; Lina Jandorf; Tiffani DeMarco; Marie Wood; Wendy McKinnon; Judy Garber; Shelley R McCormick; Marc D Schwartz
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

7.  Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.

Authors:  Anne-Deborah Bouhnik; Khadim N'Diaye; D Gareth Evans; Hilary Harris; Aad Tibben; Christi van Asperen; Joerg Schmidtke; Irmgard Nippert; Julien Mancini; Claire Julian-Reynier
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

8.  Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system.

Authors:  Petra W C Lee; Angela C Bedard; Setareh Samimi; Vivienne K Beard; Quan Hong; James E J Bedard; Blake Gilks; David F Schaeffer; Robert Wolber; Janice S Kwon; Howard J Lim; Sophie Sun; Kasmintan A Schrader
Journal:  Cancer Med       Date:  2020-07-23       Impact factor: 4.452

Review 9.  Finding all BRCA pathogenic mutation carriers: best practice models.

Authors:  Nicoline Hoogerbrugge; Marjolijn Cj Jongmans
Journal:  Eur J Hum Genet       Date:  2016-09       Impact factor: 4.246
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.